Comparative Factorial Study Design of Ultrasound Guided Wrist Block for Hand Surgery Comparing Effect of Bupivacane Alone and Bupivacane With Dexamethasone and Bupivacane With Dexametmiodine and Bupivacane With Dexamethasone and Dexametmiodine
September 16, 2026 updated by: Mahmoud Rafaat Mohamed
A Comparative Factorial Study Design of Adjuvant Enhanced Ultrasound-Guided Wrist Block Anaesthesia for Hand Surgery : Bupivacane, Dexamethasone, Dexametmiodine
Ultrasound guided wrist block comparing effect of bupivacane alone and bupivacane with dexamethasone and bupivacane with dexametmiodine and bupivacane with dexamethasone and dexametmiodine
Study Overview
Status
Completed
Conditions
Intervention / Treatment
- Procedure: Group 1: ultrasound guided wrist block with bupivacane alone
- Procedure: Group 2 : ultrasound guided wrist block with bupivacane and dexamethasone
- Procedure: Group 3: ultrasound guided wrist block with bupivacane and dexametmiodine
- Procedure: Group 4: patients will receive ultrasound guided wrist block with bupivacane and dexamethasone and dexametmiodine
Detailed Description
Ultrasound guided wrist block comparing effect of bupivacane alone and bupivacane with dexamethasone and bupivacane with dexametmiodine and bupivacane with dexametmiodine and dexamethasone.
Taking medical and surgical history from patients. Taking base line data as heart rate and blood pressure and spo2. Measure duration of analgesia for post operative pain using NRS for 24 hours abd recording NRS at time interval of 2 , 4,6,12,24 hours post operative.
Any patient the NRS above 4 will receive 5 mg nalbufin . Recording patients satisfaction by a survey .
Study Type
Interventional
Enrollment (Actual)
160
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Aswan Governorate
-
Aswān, Aswan Governorate, Egypt
- Aswan university hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Patients more than or equal 18 years old and are ASA 1-3
Exclusion Criteria:
- allergy to used medication
- pre exist neuropathy
- coagulapthy
- cognitive impairment
- refusal to participate
- Failed block and requiring general anesthesia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Group 1: ultrasound guided wrist block with bupivacane alone
Group 1: ultrasound guided wrist block with bupivacane.025%
.. 15 ml volume totally
|
Ultrasound guided wrist block with 15 ml volume of bupivacane.25%
Group 2 : patients receive ultrasound guided wrist block with bupivacane.25% and 8 mg dexamethasone.. 15 ml volume totally
Group 3 will receive ultrasound guided wrist block with bupivacane.25% and 50 mcg dexametmiodine... 15 ml volume totally
Group 4 patients will receive ultrasound guided wrist block with bupivacan.25%e
and 8 mg dexamethasone and 50 mcg dexametmiodine
|
|
Active Comparator: Group2: ultrasound guided wrist block with bupivacane.25% and 8mg dexamethasone
Group 2: 40 patients receive ultrasound guided wrist block with 15 ml volume including bupivacane.25% and 8 mg dexamethasone
|
Ultrasound guided wrist block with 15 ml volume of bupivacane.25%
Group 2 : patients receive ultrasound guided wrist block with bupivacane.25% and 8 mg dexamethasone.. 15 ml volume totally
Group 3 will receive ultrasound guided wrist block with bupivacane.25% and 50 mcg dexametmiodine... 15 ml volume totally
Group 4 patients will receive ultrasound guided wrist block with bupivacan.25%e
and 8 mg dexamethasone and 50 mcg dexametmiodine
|
|
Active Comparator: Group 3: ultrasound guided wrist block with bupivacane and dexametmiodine
Group 3: 40 patients receive ultrasound guided wrist block with 15 ml volume totally including bupivacane.25% and 50 mcg dexametmiodine
|
Ultrasound guided wrist block with 15 ml volume of bupivacane.25%
Group 2 : patients receive ultrasound guided wrist block with bupivacane.25% and 8 mg dexamethasone.. 15 ml volume totally
Group 3 will receive ultrasound guided wrist block with bupivacane.25% and 50 mcg dexametmiodine... 15 ml volume totally
Group 4 patients will receive ultrasound guided wrist block with bupivacan.25%e
and 8 mg dexamethasone and 50 mcg dexametmiodine
|
|
Active Comparator: Group 4: ultrasound guided wrist block with bupivacane and dexametmiodine and dexamethasone
Group 4 : 40 patients receive ultrasound guided wrist block with 15 ml volume including bupivacane.25% and 8 mg dexamethasone and 50 mcg dexametmiodine
|
Ultrasound guided wrist block with 15 ml volume of bupivacane.25%
Group 2 : patients receive ultrasound guided wrist block with bupivacane.25% and 8 mg dexamethasone.. 15 ml volume totally
Group 3 will receive ultrasound guided wrist block with bupivacane.25% and 50 mcg dexametmiodine... 15 ml volume totally
Group 4 patients will receive ultrasound guided wrist block with bupivacan.25%e
and 8 mg dexamethasone and 50 mcg dexametmiodine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
dexamethasone × dexmedetomidine interaction on duration of postoperative analgesia, defined as the time from completion of the block to the first request for rescue analgesia.
Time Frame: defined as the time from block administration to first request of analgesia during the first 24 hour
|
defined as the time from block administration to first request of analgesia
|
defined as the time from block administration to first request of analgesia during the first 24 hour
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Zaher Zaki Zaher, Specialist
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 30, 2025
Primary Completion (Actual)
March 30, 2026
Study Completion (Actual)
March 30, 2026
Study Registration Dates
First Submitted
February 10, 2025
First Submitted That Met QC Criteria
February 10, 2025
First Posted (Actual)
February 14, 2025
Study Record Updates
Last Update Posted (Actual)
September 17, 2026
Last Update Submitted That Met QC Criteria
September 16, 2026
Last Verified
August 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 963-9-24
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.